In recent trading, Dyne Therapeutics (DYN, Financial) experienced a significant stock movement with a sharp decline of 5.13%, bringing the share price to $30.70. The trading volume reached 341,692 shares, resulting in a turnover rate of 0.34% and a price fluctuation amplitude of 4.40%.
According to the latest financial report, Dyne Therapeutics reported no revenue and a net loss of $65.10 million, translating to an earnings per share (EPS) of -$0.70. The company also reported a gross loss of $400,000. The price-to-earnings (P/E) ratio stands at -8.63. Despite the challenging financial metrics, 90% of the ten institutions rating the stock still recommend a "buy," while 10% suggest a "hold," with no institutions advising a "sell."
Dyne Therapeutics operates within the biotechnology sector, which overall posted a modest increase of 0.06%. Some notable performances in related stocks include Monopar Therapeutics Inc. and Psyence Biomedical Ltd, which saw significant gains. Monopar Therapeutics Inc., in particular, demonstrated high activity levels with a turnover rate of 275.77% and the largest price fluctuation of 679.91% among peers.
Dyne Therapeutics focuses on addressing gene-driven diseases, targeting muscle conditions such as myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company is advancing clinical trials for its candidates, DYNE-101 and DYNE-251, which are currently in Phase 1/2 trials.
